Stanford researchers have developed a patented, wearable, haptic feedback device that provides position and velocity information on the limbs and torso by imparting rotational skin stretch.
Heart failure is a complex cardiovascular disease that affects 26 million people worldwide and is characterized by the inability of the heart to pump blood effectively, leading to a decline in its normal functions.
Aging-associated mitochondrial dysfunction (mito-dysfunction) affects every cell system in our body. Mito-dysfunction includes reduced quality of mitochondrial DNA (mtDNA), irregular generation of reactive oxygen species, and membrane potential.
Stanford researchers in the KC Huang Lab have patented a method that identifies functionally conserved protein regions with recurrent genomic alterations in cohort studies using natural variations in genomic sequences, which allows for the discovery and further understanding o
In light of the opioid epidemic within the United States, Dr. Eric Gross and colleagues developed a non-opioid therapeutic that reduces pain (Stanford Medicine Press Release).
Mice heterozygous for the targeted allele are viable and fertile. This polyubiquitin B (Ubb) mutation is characterized by a GFP-puror fusion protein "knock-in" allele that also abolishes endogenous gene function.
Stanford scientists have developed a high throughput screening method to identify therapeutics known as translational activators to treat protein synthesis disorders and ribosomopathies.
Stanford researchers in Prof. Engleman and Reticker-Flynn's labs have created a novel cell therapy that targets the T-antigen, a prominent tumor-specific antigen, by leveraging the high avidity interactions between lectins and glycans.
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Stanford researchers have defined subgroups of regulatory T cell (Tregs), CD39+ and CD39-, that can be genetically engineered to produce enhanced or reduced cytotoxicity without affecting their ability to suppress the immune system.
Scientists in the Carette Lab at Stanford have developed AAV-Titer cell lines that enable (1) improved and standardized in vitro potency assays (2) determination of a functional titer of AAV vectors of different serotypes and containing different promotors.